The global hyaluronic viscosupplementation market was valued at US$ 2.3 Billion in 2022 and is expected to reach US$ 4.0 Billion by 2033. The three injection knee hyaluronic acid injections with around 49.1% in terms of value share, has topped the global Market within the product category in 2022 and is expected to grow at a CAGR of close to 5.2% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 2.3 Billion |
| Market Value 2023 | US$ 2.4 Billion |
| Market Value 2033 | US$ 4.0 Billion |
| CAGR 2023 to 2033 | 5.2% |
| Market Share of Top 5 Countries | 73.2% |
| Key Market Players | Anika Therapeutics Inc., Zimmer Biomet, Sanofi S.A., LG Chem, Chugai Pharmaceutical Co., Ltd., Meiji Seika Pharma co. ltd, Ferring B.V., Hanmi Pharm.Co.,Ltd., Anika Therapeutics, Inc., Fidia Farmaceutici s.p.a., Bioventus LLC, OrthogenRx, Seikagaku Corporation, Bioiberica S.A.U., APTISSEN, Hangzhou Singclean Medical Products Co.,Ltd, Maxigen Biotech Inc., TRB Chemedica International SA, Yuria-Pharm LLC, Haohai Biological Technology, and Chroma Pharma |
The injection of exogenous hyaluronic acid into diarthrodial joints restores synovial fluid characteristics, generating mechanical, analgesic, anti-inflammatory, and chondroprotective benefits. Hyaluronic acid is a polymer with a high viscosity and spatial structure. Rapid rehabilitation using hyaluronic acid filler offers relief from knee osteoarthritis, benefiting rheumatologists, rehabilitation providers, and primary care providers.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for hyaluronic viscosupplementation was around 24.4% of the overall US$ 9.56 Billion of the global hyaluronic acid based products market in 2022.
Knee osteoarthritis is a chronic degenerative condition that affects the structure of the joints and causes inflammation, leading to joint discomfort and functional restrictions. Significant population globally suffers from osteoarthritis, a multifactorial origin joint disease, with high prevalence in adults.
Because of its low allergic reaction rate, simplicity of injection, speedy recovery, repeatability, and quick effects, hyaluronic acid filler has gained popularity. Hyaluronic acid injections into the joints are another common procedure, particularly for individuals with osteoarthritis of the knees. In light of doctors' general reluctance to provide repeated injection of intra-articular corticosteroid injections, hyaluronic acid injection as a non-surgical therapeutic option have gained large popularity.
Owed to the above factors, the global market is projected to grow at CAGR of 5.2% in forecasted period.
Viscosupplementation offers a structural benefit in knee osteoarthritis treatment, with improved visual appearance and increased cartilage volume. One year after treatment, joint surface reconstitutes, with reduced loss of joint space. This results in a cost-effectiveness relationship and potential delay in total knee arthroplasty. First-line therapy for OA focuses on joint preservation and alleviating symptoms. Intra-articular hyaluronic acid injections (IAHA) are a promising nonsurgical treatment, particularly for mild-to-moderate OA and severe OA with comorbidities.
IAHA, a nonsurgical treatment modality, has gained popularity in managing knee OA, despite the lack of established disease-modifying treatments. Surgical methods for total knee replacement (TKR) are successful, although they have a risk-benefit ratio. Although intra-articular hyaluronic acid (IAHA) therapy or viscosupplementation have grown in recognition, there isn't enough solid research to back up their efficacy and safety.
IAHA gives patients with knee OA a little clinical benefit without safety issues, whereas viscosupplementation has a substantial benefit-to-risk ratio and speeds up TKR. IAHA improves knee OA by allowing lubrication, shock absorption, and re-establishing joint homeostasis through induction of endogenous HA production. It reduces analgesic usage to half and leads to a 40-month improvement in pain and joint function.
Price and synthesis of HA products vary, with some made synthetically through biotechnology, while others are derived from animals. These differences impact the healthcare system's economic impact. Stabilized hyaluronic acid, a new generation of HA preparations, offers a long half-life and high density, reducing injections and puncture risk in osteoarthritis treatment. Viscosupplementation saves money in the long run by postponing surgery for severe pain, allowing therapeutic prosthesis installation, and enhancing the patient's quality of life.
Principal Consultant
National and international guidelines discourage intra-articular hyaluronic acid derivatives. In countries like England, viscosupplementation is given low NHS funding priority due to the Institute's recommendation. HA injections in the knees are frequently associated with poor tolerance and failure rates, with anteromedial injections exhibiting up to 30% local reaction rates.
The efficacy of viscosupplementation is being questioned, which might be attributed to improper usage or a poorly fitted patient OA profile. A qualified expert is required for HA injection, which is difficult in a non-swollen joint. Some of research published claim hyaluronic viscosupplementation to be ineffective in osteoarthritis, these factors act as restraints for demand of hyaluronic viscosupplements.
The USA occupies 50.0% of market share in 2022 globally. As per British Medical Journal (BMJ-Clinical research ed.) 2022, Medicare, and commercial insurance companies increased viscosupplementation coverage, with hyaluronic acid injections becoming first-line treatment for knee osteoarthritis.
This makes USA prominent market for hyaluronic viscosupplementation in North America.
Japan expenditure on hyaluronic viscosupplementation in 2022 was US$ 198.4 Million.
OA education, weight management, self-management, and exercise are crucial for improving knee OA. However, few patients are willing to undergo surgery, especially in Japan. Surgeons may delay surgery for elderly or unwilling patients, and there is a disconnect between physicians and patients. Improved communication between physicians and patients is needed to better understand the potential benefits of surgery. This makes Japan a Lucrative market for hyaluronic viscosupplementation market.
In 2022, the China held a significant share in the East Asia market and contributed around US$ 157.8 Million. China faces a significant burden of knee osteoarthritis, affecting 250 million people worldwide and causing disability.
With a large population, more patients may require rehabilitation treatment and replacement, posing a significant public health burden for China. This makes China a large market for hyaluronic viscosupplements.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By product, three injection knee hyaluronic acid injections held 49.1% market share in world in 2022.
These injections were generally safe and showed a significant improvement in pain only at 6 months. However, more than or 5 injections were associated with a higher risk of treatment-related adverse events. Thus, demand for three injection knee hyaluronic acid injections are predicted to expand rapidly between 2023 and 2033.
Why Molecular Weight is Preferred Prominently in Hyaluronic Viscosupplementation?
The market value of high molecular weight hyaluronic viscosupplementation is US$ 1.6 Billion, representing a sizable 68.8% market share in 2022. Hyaluronic acid is a high molecular weight polysaccharide used in various applications. The topic of molecular weight and hyaluronic acid's protective physicochemical functions remains controversial.
Most studies show a direct correlation between molecular weight and its effects on synoviocytes. However, some authors believe in vivo effects may differ due to excessive molecular size, preventing its ability to move from intra-articular to intercellular environments. The relationship between molecular weight and analgesia is evident in both in vitro and in vivo results, with products with molecular weight between 0.5 and 1 x 106 Da showing the best in vivo effects. Hence, high molecular weight hyaluronic viscosupplementation is preferred prominently.
By body part, the knee accounted for the prominent share in the global hyaluronic viscosupplementation market, with a revenue share of 85.2% in 2022. This segment is expected to continue holding prominent market share by the end of forecast period.
Viscosupplementation is an outpatient procedure for knees, with application method well established. Quantity and frequency depend on product characteristics and professional experience. Viscosupplementation in knee osteoarthritis has been observed to increase cartilage volume, with biopsies showing better matrix quality and increased chondrocyte density. This treatment may present a cost-effectiveness relationship, potentially reducing joint space loss.
The ambulatory surgical centers have a considerable presence in the hyaluronic viscosupplementation market, accounting for 31.7% value share in 2022, and exhibiting a high CAGR of 5.5% over the forecast period. Pseudosepsis cases submitted to the FDA, including those involving injections of non-cross-linked hyaluronic acid, necessitate rehabilitative therapy and anti-inflammatory medications. Ambulatory surgical centers offer expert guidance and 24/7 care, benefiting end users in the hyaluronic viscosupplementation market.
Collaborations and collaborations among healthcare providers, research institutions, and technology businesses can encourage innovation and hasten hyaluronic viscosupplementation. Collaboration in research, development, and commercialization can lead to market expansion and the creation of new applications. Numerous large firms compete in the field of hyaluronic viscosupplementation. Among the well-known players in this field are:
Similarly, recent developments related to the company’s manufacturing the hyaluronic viscosupplementation injections have been tracked by the team at Future Market Insights, which are available in the full report.
| Attributes | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | US$ Million for Value, Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, United Kingdom, Spain, BENELUX, Russia, Nordics, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Israel, Northern Africa and South Africa. |
| Key Market Segments Covered | Product, Body Part, Molecular Weight, Indication, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market registers US$ 2.4 billion in revenue in 2023.
The global market revenue is projected to exceed US$ 4.0 billion by 2033.
Sales of hyaluronic viscosupplementation is expected to record a 5.2% CAGR through 2033.
Hyaluronic viscosupplementation boasts substantial revenue prospects in Japan.
The market secured US$ 2.3 billion revenue in 2022.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Application of HA and its derivatives 4.2. Available Treatment for Knee Osteoarthritis 4.3. Disease Epidemiology by Key Country 4.4. Current and proposed pathways leading to the Frozen Shoulder Syndrome 4.5. Product Adoption Analysis, By Region 4.6. Pipeline Assessment 4.7. Regulatory Scenario, By Country 4.8. White Space Opportunities 4.9. Product v/s Generation Matrix 4.10. Reimbursement Landscape by Country 4.11. Porter’s Analysis 4.12. PESTLE Analysis 4.13. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure Outlook 5.1.2. Global Life Expectancy Outlook 5.1.3. Global Geriatric Population Overview 5.1.4. Global Hyaluronic Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Historical Growth of Top Companies 5.2.2. Ease of Treatment in Outpatient Basis 5.2.3. Healthcare Bodies Advocating Adoption of Combat Methodological Approach 5.2.4. Increased Treatment Efficiency 5.2.5. Rising Prevalence of Knee Osteoarthritis 5.2.6. Treatment Costs 5.2.7. Increasing Minimally Invasive Treatment Options 5.2.8. Improved Access to Healthcare Services 5.2.9. Integration of Digital Health Technologies 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Volume (Units) Analysis, 2012 to 2022 6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market – Pricing Analysis 7.1. Regional Pricing Analysis By Product 7.2. Global Average Pricing Analysis Benchmark 7.3. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033 8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 8.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 8.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Product, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033 9.3.1. Single Injection Knee Hyaluronic Acid Injections 9.3.2. Three Injection Knee Hyaluronic Acid Injections 9.3.3. Five Injection Knee Hyaluronic Acid Injections 9.3.4. Next Generation (Steroid Combination) 9.4. Market Attractiveness Analysis By Product 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Body Part 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Body Parts, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Body Parts, 2023 to 2033 10.3.1. Knee 10.3.2. Hip 10.3.3. Shoulder 10.3.4. Small Joints 10.3.5. Others 10.4. Market Attractiveness Analysis By Body Parts 11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Molecular Weight 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Molecular Weight, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Molecular Weight, 2023 to 2033 11.3.1. High Molecular Weight 11.3.2. Medium Molecular Weight 11.3.3. Low Molecular Weight 11.4. Market Attractiveness Analysis By Molecular Weight 12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Indication 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Indication, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 12.3.1. Knee Osteoarthritis 12.3.2. Tendinopathies 12.3.3. Shoulder Arthritis 12.3.4. Hip Osteoarthritis 12.3.5. Frozen Shoulder 12.3.6. Ligament Injury 12.3.7. Post-Arthroscopy 12.3.8. Others 12.4. Market Attractiveness Analysis By Indication 13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 13.3.1. Hospitals 13.3.2. Ambulatory Surgical Centers 13.3.3. Orthopedic Clinics 13.3.4. Retail Pharmacies 13.3.5. Online Sales 13.4. Market Attractiveness Analysis By End User 14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis Forecast By Region, 2023 to 2033 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. South Asia 14.3.5. East Asia 14.3.6. Oceania 14.3.7. Middle East and Africa 14.4. Market Attractiveness Analysis By Region 15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction / Key Findings 15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. USA. 15.3.1.2. Canada 15.3.2. By Product 15.3.3. By Body Parts 15.3.4. By Molecular Weight 15.3.5. By Indication 15.3.6. By End User 15.4. Market Attractiveness Analysis By Region 15.4.1. By Country 15.4.2. By Product 15.4.3. By Body Parts 15.4.4. By Molecular Weight 15.4.5. By Indication 15.4.6. By End User 15.5. Market trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. USA. Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Product 15.8.1.2.2. By Body Parts 15.8.1.2.3. By Molecular Weight 15.8.1.2.4. By Indication 15.8.1.2.5. By End User 15.8.2. Canada Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Product 15.8.2.2.2. By Body Parts 15.8.2.2.3. By Molecular Weight 15.8.2.2.4. By Indication 15.8.2.2.5. By End User 16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction / Key Findings 16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Brazil 16.3.1.2. Mexico 16.3.1.3. Argentina 16.3.1.4. Rest of Latin America 16.3.2. By Product 16.3.3. By Body Parts 16.3.4. By Molecular Weight 16.3.5. By Indication 16.3.6. By End User 16.4. Market Attractiveness Analysis By Region 16.4.1. By Country 16.4.2. By Product 16.4.3. By Body Parts 16.4.4. By Molecular Weight 16.4.5. By Indication 16.4.6. By End User 16.5. Market trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. Brazil Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Product 16.8.1.2.2. By Body Parts 16.8.1.2.3. By Molecular Weight 16.8.1.2.4. By Indication 16.8.1.2.5. By End User 16.8.2. Mexico Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Product 16.8.2.2.2. By Body Parts 16.8.2.2.3. By Molecular Weight 16.8.2.2.4. By Indication 16.8.2.2.5. By End User 16.8.3. Argentina Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Product 16.8.3.2.2. By Body Parts 16.8.3.2.3. By Molecular Weight 16.8.3.2.4. By Sample 16.8.3.2.5. By End User 17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction / Key Findings 17.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. France 17.3.1.3. Spain 17.3.1.4. Russia 17.3.1.5. Italy 17.3.1.6. BENELUX 17.3.1.7. United Kingdom. 17.3.1.8. Nordics 17.3.1.9. Rest of Europe 17.3.2. By Product 17.3.3. By Body Parts 17.3.4. By Molecular Weight 17.3.5. By Indication 17.3.6. By End User 17.4. Market Attractiveness Analysis By Region 17.4.1. By Country 17.4.2. By Product 17.4.3. By Body Parts 17.4.4. By End User 17.5. Market trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Germany Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Product 17.8.1.2.2. By Body Parts 17.8.1.2.3. By Molecular Weight 17.8.1.2.4. By Indication 17.8.1.2.5. By End User 17.8.2. France Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Product 17.8.2.2.2. By Body Parts 17.8.2.2.3. By Molecular Weight 17.8.2.2.4. By Indication 17.8.2.2.5. By End User 17.8.3. Spain Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Product 17.8.3.2.2. By Body Parts 17.8.3.2.3. By Molecular Weight 17.8.3.2.4. By Sample 17.8.3.2.5. Type By End User 17.8.4. Russia Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Product 17.8.4.2.2. By Body Parts 17.8.4.2.3. By Molecular Weight 17.8.4.2.4. By Sample 17.8.4.2.5. Type By End User 17.8.5. Italy Market Analysis 17.8.5.1. Introduction 17.8.5.2. Market Analysis and Forecast by Market Taxonomy 17.8.5.2.1. By Product 17.8.5.2.2. By Body Parts 17.8.5.2.3. By Molecular Weight 17.8.5.2.4. By Indication 17.8.5.2.5. By End User 17.8.6. BENELUX Market Analysis 17.8.6.1. Introduction 17.8.6.2. Market Analysis and Forecast by Market Taxonomy 17.8.6.2.1. By Product 17.8.6.2.2. By Body Parts 17.8.6.2.3. By Molecular Weight 17.8.6.2.4. By Indication 17.8.6.2.5. By End User 17.8.7. United Kingdom. Market Analysis 17.8.7.1. Introduction 17.8.7.2. Market Analysis and Forecast by Market Taxonomy 17.8.7.2.1. By Product 17.8.7.2.2. By Body Parts 17.8.7.2.3. By Molecular Weight 17.8.7.2.4. By Indication 17.8.7.2.5. By End User 17.8.8. Nordics Market Analysis 17.8.8.1. Introduction 17.8.8.2. Market Analysis and Forecast by Market Taxonomy 17.8.8.2.1. By Product 17.8.8.2.2. By Body Parts 17.8.8.2.3. By Molecular Weight 17.8.8.2.4. By Indication 17.8.8.2.5. By End User 18. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18.1. Introduction / Key Findings 18.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. China 18.3.1.2. Japan 18.3.1.3. South Korea 18.3.2. By Product 18.3.3. By Body Parts 18.3.4. By Molecular Weight 18.3.5. By Indication 18.3.6. By End User 18.4. Market Attractiveness Analysis By Region 18.4.1. By Country 18.4.2. By Product 18.4.3. By Body Parts 18.4.4. By Molecular Weight 18.4.5. By Indication 18.4.6. By End User 18.5. Market trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. China Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Product 18.8.1.2.2. By Body Parts 18.8.1.2.3. By Molecular Weight 18.8.1.2.4. By Indication 18.8.1.2.5. By End User 18.8.2. Japan Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Product 18.8.2.2.2. By Body Parts 18.8.2.2.3. By Molecular Weight 18.8.2.2.4. By Indication 18.8.2.2.5. By End User 18.8.3. South Korea Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Product 18.8.3.2.2. By Body Parts 18.8.3.2.3. By Molecular Weight 18.8.3.2.4. By Indication 18.8.3.2.5. By End User 19. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 19.1. Introduction / Key Findings 19.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. India 19.3.1.2. Indonesia 19.3.1.3. Thailand 19.3.1.4. Philippines 19.3.1.5. Malaysia 19.3.1.6. Vietnam 19.3.1.7. Rest of South Asia 19.3.2. By Product 19.3.3. By Body Parts 19.3.4. By Molecular Weight 19.3.5. By Indication 19.3.6. By End User 19.4. Market Attractiveness Analysis By Region 19.4.1. By Country 19.4.2. By Product 19.4.3. By Body Parts 19.4.4. By Molecular Weight 19.4.5. By Indication 19.4.6. By End User 19.5. Market trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. India Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Product 19.8.1.2.2. By Body Parts 19.8.1.2.3. By Molecular Weight 19.8.1.2.4. By Indication 19.8.1.2.5. By End User 19.8.2. Indonesia Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Product 19.8.2.2.2. By Body Parts 19.8.2.2.3. By Molecular Weight 19.8.2.2.4. By Indication 19.8.2.2.5. By End User 19.8.3. Thailand Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Product 19.8.3.2.2. By Body Parts 19.8.3.2.3. By Molecular Weight 19.8.3.2.4. By Indication 19.8.3.2.5. By End User 19.8.4. Philippines Market Analysis 19.8.4.1. Introduction 19.8.4.2. Market Analysis and Forecast by Market Taxonomy 19.8.4.2.1. By Product 19.8.4.2.2. By Body Parts 19.8.4.2.3. By Molecular Weight 19.8.4.2.4. By Indication 19.8.4.2.5. By End User 19.8.5. Malaysia Market Analysis 19.8.5.1. Introduction 19.8.5.2. Market Analysis and Forecast by Market Taxonomy 19.8.5.2.1. By Product 19.8.5.2.2. By Body Parts 19.8.5.2.3. By Molecular Weight 19.8.5.2.4. By Indication 19.8.5.2.5. By End User 19.8.6. Vietnam Market Analysis 19.8.6.1. Introduction 19.8.6.2. Market Analysis and Forecast by Market Taxonomy 19.8.6.2.1. By Product 19.8.6.2.2. By Body Parts 19.8.6.2.3. By Molecular Weight 19.8.6.2.4. By Indication 19.8.6.2.5. By End User 20. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 20.1. Introduction / Key Findings 20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 20.3. Current and Future Market Size (US$ Million) Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. Australia 20.3.1.2. New Zealand 20.3.2. By Product 20.3.3. By Body Parts 20.3.4. By Molecular Weight 20.3.5. By Indication 20.3.6. By End User 20.4. Market Attractiveness Analysis By Region 20.4.1. By Country 20.4.2. By Product 20.4.3. By Body Parts 20.4.4. By End User 20.5. Market trends 20.6. Key Market Participants - Intensity Mapping 20.7. Drivers and Restraints - Impact Analysis 20.8. Country Level Analysis & Forecast 20.8.1. Australia Market Analysis 20.8.1.1. Introduction 20.8.1.2. Market Analysis and Forecast by Market Taxonomy 20.8.1.2.1. By Product 20.8.1.2.2. By Body Parts 20.8.1.2.3. By Molecular Weight 20.8.1.2.4. By Indication 20.8.1.2.5. By End User 20.8.2. New Zealand Market Analysis 20.8.2.1. Introduction 20.8.2.2. Market Analysis and Forecast by Market Taxonomy 20.8.2.2.1. By Product 20.8.2.2.2. By Body Parts 20.8.2.2.3. By Molecular Weight 20.8.2.2.4. By Indication 20.8.2.2.5. By End User 21. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033 21.1. Introduction / Key Findings 21.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 21.3. Current and Future Market Size (US$ Million) Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 21.3.1. By Country 21.3.1.1. GCC Countries 21.3.1.2. Türkiye 21.3.1.3. Israel 21.3.1.4. South Africa 21.3.1.5. Northern Africa 21.3.1.6. Rest of Middle East and Africa 21.3.2. By Product 21.3.3. By Body Parts 21.3.4. By Molecular Weight 21.3.5. By Indication 21.3.6. By End User 21.4. Market Attractiveness Analysis By Region 21.4.1. By Country 21.4.2. By Product 21.4.3. By Body Parts 21.4.4. By Molecular Weight 21.4.5. By Indication 21.4.6. By End User 21.5. Market trends 21.6. Key Market Participants - Intensity Mapping 21.7. Drivers and Restraints - Impact Analysis 21.8. Country Level Analysis & Forecast 21.8.1. GCC Countries Market Analysis 21.8.1.1. Introduction 21.8.1.2. Market Analysis and Forecast by Market Taxonomy 21.8.1.2.1. By Product 21.8.1.2.2. By Body Parts 21.8.1.2.3. By Molecular Weight 21.8.1.2.4. By Indication 21.8.1.2.5. By End User 21.8.2. Türkiye Market Analysis 21.8.2.1. Introduction 21.8.2.2. Market Analysis and Forecast by Market Taxonomy 21.8.2.2.1. By Product 21.8.2.2.2. By Body Parts 21.8.2.2.3. By Molecular Weight 21.8.2.2.4. By Indication 21.8.2.2.5. By End User 21.8.3. Israel Market Analysis 21.8.3.1. Introduction 21.8.3.2. Market Analysis and Forecast by Market Taxonomy 21.8.3.2.1. By Product 21.8.3.2.2. By Body Parts 21.8.3.2.3. By Molecular Weight 21.8.3.2.4. By Indication 21.8.3.2.5. By End User 21.8.4. South Africa Market Analysis 21.8.4.1. Introduction 21.8.4.2. Market Analysis and Forecast by Market Taxonomy 21.8.4.2.1. By Product 21.8.4.2.2. By Body Parts 21.8.4.2.3. By Molecular Weight 21.8.4.2.4. By Indication 21.8.4.2.5. By End User 21.8.5. Northern Africa Market Analysis 21.8.5.1. Introduction 21.8.5.2. Market Analysis and Forecast by Market Taxonomy 21.8.5.2.1. By Product 21.8.5.2.2. By Body Parts 21.8.5.2.3. By Molecular Weight 21.8.5.2.4. By Indication 21.8.5.2.5. By End User 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis of Top Players (%) 22.3. Market Concentration 22.4. Market Presence Analysis 22.4.1. Regional Footprint of Players 22.4.2. Product Footprint of Players 22.4.3. Channel Footprint of Players 23. Competition Analysis 23.1. Competition Dashboard 23.2. Key Development Analysis 23.3. Branding and Promotional Strategies, By Key Players 23.4. Competition Deep Dive 23.4.1. Anika Therapeutics 23.4.1.1. Overview 23.4.1.2. Product Portfolio 23.4.1.3. Key Financials 23.4.1.4. Sales Footprint 23.4.1.5. SWOT Analysis 23.4.1.6. Strategy Overview 23.4.1.6.1. Marketing Strategies 23.4.1.6.2. Channel Strategies 23.4.1.6.3. Product Strategies 23.4.2. Zimmer Biomet 23.4.2.1. Overview 23.4.2.2. Product Portfolio 23.4.2.3. Key Financials 23.4.2.4. Sales Footprint 23.4.2.5. SWOT Analysis 23.4.2.6. Strategy Overview 23.4.2.6.1. Marketing Strategies 23.4.2.6.2. Channel Strategies 23.4.2.6.3. Product Strategies 23.4.3. Sanofi S.A. 23.4.3.1. Overview 23.4.3.2. Product Portfolio 23.4.3.3. Key Financials 23.4.3.4. Sales Footprint 23.4.3.5. SWOT Analysis 23.4.3.6. Strategy Overview 23.4.3.6.1. Marketing Strategies 23.4.3.6.2. Channel Strategies 23.4.3.6.3. Product Strategies 23.4.4. LG Chem 23.4.4.1. Overview 23.4.4.2. Product Portfolio 23.4.4.3. Key Financials 23.4.4.4. Sales Footprint 23.4.4.5. SWOT Analysis 23.4.4.6. Strategy Overview 23.4.4.6.1. Marketing Strategies 23.4.4.6.2. Channel Strategies 23.4.4.6.3. Product Strategies 23.4.5. Chugai Pharmaceutical Co., Ltd. 23.4.5.1. Overview 23.4.5.2. Product Portfolio 23.4.5.3. Key Financials 23.4.5.4. Sales Footprint 23.4.5.5. SWOT Analysis 23.4.5.6. Strategy Overview 23.4.5.6.1. Marketing Strategies 23.4.5.6.2. Channel Strategies 23.4.5.6.3. Product Strategies 23.4.6. Meiji Seika Pharma co. ltd 23.4.6.1. Overview 23.4.6.2. Product Portfolio 23.4.6.3. Key Financials 23.4.6.4. Sales Footprint 23.4.6.5. SWOT Analysis 23.4.6.6. Strategy Overview 23.4.6.6.1. Marketing Strategies 23.4.6.6.2. Channel Strategies 23.4.6.6.3. Product Strategies 23.4.7. Ferring B.V. 23.4.7.1. Overview 23.4.7.2. Product Portfolio 23.4.7.3. Key Financials 23.4.7.4. Sales Footprint 23.4.7.5. SWOT Analysis 23.4.7.6. Strategy Overview 23.4.7.6.1. Marketing Strategies 23.4.7.6.2. Channel Strategies 23.4.7.6.3. Product Strategies 23.4.8. Hanmi Pharm.Co.,Ltd. 23.4.8.1. Overview 23.4.8.2. Product Portfolio 23.4.8.3. Key Financials 23.4.8.4. Sales Footprint 23.4.8.5. SWOT Analysis 23.4.8.6. Strategy Overview 23.4.8.6.1. Marketing Strategies 23.4.8.6.2. Channel Strategies 23.4.8.6.3. Product Strategies 23.4.9. Fidia Farmaceutici s.p.a. 23.4.9.1. Overview 23.4.9.2. Product Portfolio 23.4.9.3. Key Financials 23.4.9.4. Sales Footprint 23.4.9.5. SWOT Analysis 23.4.9.6. Strategy Overview 23.4.9.6.1. Marketing Strategies 23.4.9.6.2. Channel Strategies 23.4.9.6.3. Product Strategies 23.4.10. Bioventus LLC 23.4.10.1. Overview 23.4.10.2. Product Portfolio 23.4.10.3. Key Financials 23.4.10.4. Sales Footprint 23.4.10.5. SWOT Analysis 23.4.10.6. Strategy Overview 23.4.10.6.1. Marketing Strategies 23.4.10.6.2. Channel Strategies 23.4.10.6.3. Product Strategies 23.4.11. OrthogenRx 23.4.11.1. Overview 23.4.11.2. Product Portfolio 23.4.11.3. Key Financials 23.4.11.4. Sales Footprint 23.4.11.5. SWOT Analysis 23.4.11.6. Strategy Overview 23.4.11.6.1. Marketing Strategies 23.4.11.6.2. Channel Strategies 23.4.11.6.3. Product Strategies 23.4.12. Seikagaku Corporation 23.4.12.1. Overview 23.4.12.2. Product Portfolio 23.4.12.3. Key Financials 23.4.12.4. Sales Footprint 23.4.12.5. SWOT Analysis 23.4.12.6. Strategy Overview 23.4.12.6.1. Marketing Strategies 23.4.12.6.2. Channel Strategies 23.4.12.6.3. Product Strategies 23.4.13. Bioiberica S.A.U. 23.4.13.1. Overview 23.4.13.2. Product Portfolio 23.4.13.3. Key Financials 23.4.13.4. Sales Footprint 23.4.13.5. SWOT Analysis 23.4.13.6. Strategy Overview 23.4.13.6.1. Marketing Strategies 23.4.13.6.2. Channel Strategies 23.4.13.6.3. Product Strategies 23.4.14. APTISSEN 23.4.14.1. Overview 23.4.14.2. Product Portfolio 23.4.14.3. Key Financials 23.4.14.4. Sales Footprint 23.4.14.5. SWOT Analysis 23.4.14.6. Strategy Overview 23.4.14.6.1. Marketing Strategies 23.4.14.6.2. Channel Strategies 23.4.14.6.3. Product Strategies 23.4.15. Hangzhou Singclean Medical Products Co.,Ltd 23.4.15.1. Overview 23.4.15.2. Product Portfolio 23.4.15.3. Key Financials 23.4.15.4. Sales Footprint 23.4.15.5. SWOT Analysis 23.4.15.6. Strategy Overview 23.4.15.6.1. Marketing Strategies 23.4.15.6.2. Channel Strategies 23.4.15.6.3. Product Strategies 23.4.16. Maxigen Biotech Inc. 23.4.16.1. Overview 23.4.16.2. Product Portfolio 23.4.16.3. Key Financials 23.4.16.4. Sales Footprint 23.4.16.5. SWOT Analysis 23.4.16.6. Strategy Overview 23.4.16.6.1. Marketing Strategies 23.4.16.6.2. Channel Strategies 23.4.16.6.3. Product Strategies 23.4.17. TRB Chemedica International SA 23.4.18. Yuria-Pharm LLC 23.4.18.1. Overview 23.4.18.2. Product Portfolio 23.4.18.3. Key Financials 23.4.18.4. Sales Footprint 23.4.18.5. SWOT Analysis 23.4.18.6. Strategy Overview 23.4.18.6.1. Marketing Strategies 23.4.18.6.2. Channel Strategies 23.4.18.6.3. Product Strategies 23.4.19. Haohai Biological Technology 23.4.19.1. Overview 23.4.19.2. Product Portfolio 23.4.19.3. Key Financials 23.4.19.4. Sales Footprint 23.4.19.5. SWOT Analysis 23.4.19.6. Strategy Overview 23.4.19.6.1. Marketing Strategies 23.4.19.6.2. Channel Strategies 23.4.19.6.3. Product Strategies 23.4.20. Chroma Pharma 23.4.20.1. Overview 23.4.20.2. Product Portfolio 23.4.20.3. Key Financials 23.4.20.4. Sales Footprint 23.4.20.5. SWOT Analysis 23.4.20.6. Strategy Overview 23.4.20.6.1. Marketing Strategies 23.4.20.6.2. Channel Strategies 23.4.20.6.3. Product Strategies 24. Assumptions and Acronyms Used 25. Research Methodology
Explore Healthcare Insights
View Reports
Hyaluronic Viscosupplementation Market
